It's hard enough to find undervalued stocks today, and a stock that is
already up more than 40% over the last year and within a few percentage
points of its 52-week high is not initially the most promising
candidate. To be sure, PRA Health Sciences (NASDAQ:PRAH)
is not conventionally cheap on backward-looking multiples and there are
valid concerns that the CRO market could be in for a harder stretch as
biotech funding dries up and Big Pharma pushes another round of
consolidation. On the other hand, PRA's strong foundation in clinical
trial management and its growing capabilities in strategic outsourcing
and data/analytics shouldn't be ignored, and I believe there are
opportunities here for the company to outgrow its addressed market.
Follow the link for more:
PRA Health Sciences' Special Mix Could Have More To Offer
No comments:
Post a Comment